FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours ner resnonse.	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Ho Tony W  (Last) (First) (Middle)  C/O CRISPR THERAPEUTICS, INC.  610 MAIN STREET						Issuer Name and Ticker or Trading Symbol CRISPR Therapeutics AG [ CRSP ]      Jate of Earliest Transaction (Month/Day/Year) 12/03/2021							(Ch	Relationship of Reporting Person(s) to Issuer Check all applicable) Director Director Director Difficer (give title Other (specify below) below)  Executive VP, Head of R&D				
(Street)  CAMBRIDGE MA 02139  (City) (State) (Zip)				_ 4. l	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	Individual or Joint/Group Filing (Check Applicable ne)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - No	n-Deri	vativ	e Se	curities	s Ac	quired,	Dis	posed o	f, or Be	neficial	ly Owned	I			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					Execution Date,		Transaction Disposed Code (Instr.		ties Acquired (A) or I Of (D) (Instr. 3, 4 and 5)		5) Securitie Benefici Owned F	5. Amount of Securities Beneficially Owned Following Reported		n: Direct r Indirect estr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	v	Amount	(A) oi (D)	Price	Transaci (Instr. 3	tion(s)			(111541.4)	
Common Shares 12/03/2					3/2021	2021		М		26,667	(1) A	(2)	64	64,971		D		
Common Shares 12/06/2				6/2021	2021		F <sup>(3)</sup>		12,607 Г		\$69.1	7 52	,364		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Date,	Code (Inst				6. Date Exercisable and Expiration Date (Month/Day/Year)		е	7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	s S Illy	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	or Number of Shares					
Restricted Stock Units	(2)	12/03/2021			M		26,667		(1)		(1)	Common Shares	26,667	(2)	13,333	3	D	

## **Explanation of Responses:**

- 1. The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022.
- 2. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

3. On December 3, 2019, the reporting person was granted 40,000 restricted stock units. On December 3, 2021, 26,667 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

## Remarks:

/s/ Michael Esposito, attorney-

12/07/2021

in-fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.